loader from loading.io

Genetic Testing Among Patients with High-Risk Breast, Ovarian, Pancreatic, and Prostate Cancers

Speaking of SurgOnc

Release Date: 02/14/2023

Docetaxel‑Based Neoadjuvant Chemotherapy Followed by En Bloc Resection for Esophageal Adenocarcinoma: A 15‑Year Retrospective Analysis from a Regional Upper Gastrointestinal Cancer Network show art Docetaxel‑Based Neoadjuvant Chemotherapy Followed by En Bloc Resection for Esophageal Adenocarcinoma: A 15‑Year Retrospective Analysis from a Regional Upper Gastrointestinal Cancer Network

Speaking of SurgOnc

Rick Greene, MD, discusses with Lorenzo Ferri, MD, PhD, the long-term survival outcomes of patients with esophageal and junctional adenocarcinoma treated with neoadjuvant docetaxel-based chemotherapy and en bloc transthoracic esophagectomy. Dr. Ferri is author of, "Docetaxel-Based Neoadjuvant Chemotherapy Followed by En Bloc Resection for Esophageal Adenocarcinoma: A 15-Year Retrospective Analysis from a Regional Upper Gastrointestinal Cancer Network." Dr. Ferri is Professor of Surgery and Oncology, McGill University; David S. Mulder Chair of Surgery Head, Division of Thoracic and Upper...

info_outline
The Landmark Series—Addressing Disparities in Breast Cancer Screening: New Recommendations for Black Women show art The Landmark Series—Addressing Disparities in Breast Cancer Screening: New Recommendations for Black Women

Speaking of SurgOnc

Rick Greene, MD, discusses with Kathie-Ann Joseph, MD, MPH, the epidemiologic and socioeconomic factors that are associated with breast cancer among black women and an assessment of the implications of these factors for screening in this population. Dr. Joseph is author of, "The Landmark Series—Addressing Disparities in Breast Cancer Screening: New Recommendations for Black Women." Dr. Joseph is Professor, Department of Surgery at NYU Grossman School of Medicine; Professor, Department of Population Health at NYU Grossman School of Medicine; and, Vice Chair for Diversity and Health Equity for...

info_outline
Standardization of Colon Resection for Cancer: An Overview of the American College of Surgeons Commission on Cancer Standard 5.6 show art Standardization of Colon Resection for Cancer: An Overview of the American College of Surgeons Commission on Cancer Standard 5.6

Speaking of SurgOnc

Rick Greene, MD, discusses with Anthony Villano, MD, a review the American College of Surgeons Commission on Cancer Standard 5.6, which pertains to curative intent colon resections performed for cancer. Dr. Villano is author of "Standardization of Colon Resection for Cancer: An Overview of the American College of Surgeons Commission on Cancer Standard 5.6." Dr. Villano is the Assistant Professor, Surgical Oncology, in the Department of Surgical Oncology, at Fox Chase Cancer Center in Philadelphia, PA.

info_outline
Hepatectomy Before Primary Tumor Resection as Preferred Approach for Synchronous Liver Metastases from Rectal Cancer show art Hepatectomy Before Primary Tumor Resection as Preferred Approach for Synchronous Liver Metastases from Rectal Cancer

Speaking of SurgOnc

Rick Greene, MD, discusses with Jean-Nicolas Vauthey, MD, a comparison of different surgical approaches to synchronous liver metastases from rectal cancer and their analysis of both clinicopathological and biological tumor factors associated with completion of the reverse approach. Professor Vauthey is the senior author of, “Hepatectomy Before Primary Tumor Resection as Preferred Approach for Synchronous Liver Metastases from Rectal Cancer.” Dr. Vauthey is Professor of Surgery and Chief of the Hepato-Pancreato-Biliary Section, and the Dallas/Fort Worth Living Legend Chair of Cancer...

info_outline
Hospital Designations and Their Impact on Guideline-Concordant Care and Survival in Pancreatic Cancer. Do They Matter? show art Hospital Designations and Their Impact on Guideline-Concordant Care and Survival in Pancreatic Cancer. Do They Matter?

Speaking of SurgOnc

Rick Greene, MD, discusses with Patricio M. Polanco, MD, an analysis of three hospital designations, as well as volume status, and their effect on the delivery of care and survival outcomes using a cancer registry database of the second largest state in the USA. Dr. Polanco is co-corresponding author of, “Hospital Designations and Their Impact on Guideline-Concordant Care and Survival in Pancreatic Cancer. Do They Matter?.”

info_outline
Benchmarks and Geographic Differences in Gallbladder Cancer Surgery: An International Multicenter Study show art Benchmarks and Geographic Differences in Gallbladder Cancer Surgery: An International Multicenter Study

Speaking of SurgOnc

Rick Greene, MD, discusses with Eduardo A. Vega, MD, definitions reported on of benchmark values for gallbladder cancer surgery across an international population as well as geographic differences in gallbladder cancer surgery across multiple continents. Dr. Vega is the senior author of, “Benchmarks and Geographic Differences in Gallbladder Cancer Surgery: An International Multicenter Study.” Dr. Vega is Assistant Professor of Surgery at Boston University School of Medicine and Hepato-Bilio-Pancreatic surgeon in the Department of Surgery at St. Elizabeth’s Medical Center, Boston, MA....

info_outline
CA19-9 Response to First-Line Neoadjuvant FOLFIRINOX and Second-Line Gemcitabine/Nab-Paclitaxel for Patients with Operable Pancreatic Cancer show art CA19-9 Response to First-Line Neoadjuvant FOLFIRINOX and Second-Line Gemcitabine/Nab-Paclitaxel for Patients with Operable Pancreatic Cancer

Speaking of SurgOnc

Rick Greene, MD, discusses with Susan Tsai, MD, MHS, the results of an analysis examining the efficacy of second-line gemcitabine/nab-paclitaxel (GnP) after first-line FOLFIRINOX in the neoadjuvant setting among patients with operable pancreatic cancer who were treated with a total neoadjuvant approach. Dr. Tsai is the senior author of, “CA19-9 Response to First-line Neoadjuvant FOLFIRINOX and Second-line Gemcitabine/nab- Paclitaxel in Patients with Operable Pancreatic Cancer.” Dr. Tsai is Professor of Surgery and Chief of the Division of Surgical Oncology at The Ohio State University...

info_outline
Neuroendocrine Tumor Liver Metastases: Long-Term Follow-up Evaluation of More Than 500 Patients show art Neuroendocrine Tumor Liver Metastases: Long-Term Follow-up Evaluation of More Than 500 Patients

Speaking of SurgOnc

Rick Greene, MD, discusses with Sean Cleary, MD, cytoreductive hepatectomy for neuroendocrine tumor liver metastases; specifically, perioperative outcomes and operative trends, rates and duration of symptomatic relief, and long-term survival and predictors of prognosis. Dr. Cleary is the senior author of, “Neuroendocrine Tumor Liver Metastases: Long-Term Follow-up Evaluation of More Than 500 Patients.” Dr. Cleary is the Bernard and Ryna Langer Chair of the Division of General Surgery in the Department of Surgery at the University of Toronto, Toronto, Canada.

info_outline
Endocrine Therapy for Surgeons: Practical Pearls for Managing Menopausal, Bone Loss and Sexual Adverse Effects show art Endocrine Therapy for Surgeons: Practical Pearls for Managing Menopausal, Bone Loss and Sexual Adverse Effects

Speaking of SurgOnc

Rick Greene, MD, discusses with Anna Weiss, MD, the evidence-based treatments available for the adverse effects of endocrine therapy that can be experienced by breast cancer patients, including clear treatment algorithms for genitourinary syndrome of menopause (GSM), which can be overlooked by providers. Dr. Weiss is the senior author of, “Endocrine Therapy for Surgeons: Practical Pearls for Managing Menopausal, Bone Loss and Sexual Adverse Effects.” Dr. Weiss is Associate Professor of Surgery and Medicine, and Director of the Wilmot Cancer Institute Comprehensive Breast Cancer Program at...

info_outline
Impact of the Histologic Pattern of Residual Tumor After Neoadjuvant Chemotherapy on Recurrence and Survival in Stage I–III Breast Cancer show art Impact of the Histologic Pattern of Residual Tumor After Neoadjuvant Chemotherapy on Recurrence and Survival in Stage I–III Breast Cancer

Speaking of SurgOnc

Rick Greene, MD, and Tari King, MD, FSSO, discuss findings generated from central path review of a large series of patients treated with neoadjuvant chemotherapy and surgery regarding the pattern of residual tumor in the breast and its related prognostic significance. Dr. King is the senior author of, “Impact of the Histologic Pattern of Residual Tumor After Neoadjuvant Chemotherapy on Recurrence and Survival in Stage I–III Breast Cancer.” Dr. Tari A. King is the Anne E. Dyson Professor of Surgery at Harvard Medical School, the chief of the Division of Breast Surgery and the vice chair...

info_outline
 
More Episodes

Rick Greene, MD, discusses with Meghan R. Flanagan, MD, MPH, the results of a retrospective population-based study about genetic testing among patients with breast, ovarian, pancreatic and prostate cancers. Dr. Flanagan is author of, “Genetic Testing Among Patients with High-Risk Breast, Ovarian, Pancreatic, and Prostate Cancers.”

Dr. Flanagan is Assistant Professor of Surgery at the University of Washington School of Medicine, Seattle, WA.

http://doi.org/10.1245/S10434-022-12755-Y